Tags

Type your tag names separated by a space and hit enter

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Pharmacol Ther. 2008 Jan; 117(1):77-93.P&T

Abstract

Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by an immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (S1P) receptors. Here, we outline the direct roles that S1P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS.

Authors+Show Affiliations

Department of Anatomy and Neuroscience, University College Cork, Windle Building, Cork, Ireland. k.dev@ucc.ieNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17961662

Citation

Dev, Kumlesh K., et al. "Brain Sphingosine-1-phosphate Receptors: Implication for FTY720 in the Treatment of Multiple Sclerosis." Pharmacology & Therapeutics, vol. 117, no. 1, 2008, pp. 77-93.
Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117(1):77-93.
Dev, K. K., Mullershausen, F., Mattes, H., Kuhn, R. R., Bilbe, G., Hoyer, D., & Mir, A. (2008). Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacology & Therapeutics, 117(1), 77-93.
Dev KK, et al. Brain Sphingosine-1-phosphate Receptors: Implication for FTY720 in the Treatment of Multiple Sclerosis. Pharmacol Ther. 2008;117(1):77-93. PubMed PMID: 17961662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. AU - Dev,Kumlesh K, AU - Mullershausen,Florian, AU - Mattes,Henri, AU - Kuhn,Rainer R, AU - Bilbe,Graeme, AU - Hoyer,Daniel, AU - Mir,Anis, Y1 - 2007/09/08/ PY - 2007/08/16/received PY - 2007/08/16/accepted PY - 2007/10/27/pubmed PY - 2008/3/12/medline PY - 2007/10/27/entrez SP - 77 EP - 93 JF - Pharmacology & therapeutics JO - Pharmacol. Ther. VL - 117 IS - 1 N2 - Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by an immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (S1P) receptors. Here, we outline the direct roles that S1P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS. SN - 0163-7258 UR - https://www.unboundmedicine.com/medline/citation/17961662/Brain_sphingosine_1_phosphate_receptors:_implication_for_FTY720_in_the_treatment_of_multiple_sclerosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(07)00173-8 DB - PRIME DP - Unbound Medicine ER -